Screening for factor V Leiden mutation before prescribing combination oral contraceptives

Fertility and Sterility

Volumn 72, Issue 4, 1999, Pages 646-651

  Creinin, Mitchell D ^a   Lisman, Rachel ^a   Strickler, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Factor V Leiden; Hypercoagulability; Oral contraceptives; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT;

ADULT; ANAMNESIS; ARTICLE; BLOOD CLOTTING FACTOR DEFICIENCY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH CARE COST; HUMAN; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; COST-BENEFIT ANALYSIS; FACTOR V; FEMALE; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; MUTATION; PRESCRIPTIONS, DRUG; THROMBOEMBOLISM;

EID: 0033214004     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00318-0     Document Type: Article

References (30)

1. FDA Talk Paper. Oral Contraceptives and Risk of Blood Clots. Nov. 14, 1995. Available at http://www.fda.gov/bbs/topics/ANSWERS/ANS00694.html. Accessed on July 16, 1998.
2. Henshaw S.K. Unintended pregnancy in the United States. Fam Plann Perspect. 30:1998;24-29.
3. Piccinino L.J., Mosher W.D. Trends in contraceptive use in the United States 1982-1995. Fam Plann Perspect. 30:1998;4-10.
4. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1995;1582-1588.
5. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasiladis C. Risk of idiopathic cardiovascular death and non-fatal thromboembolism in women using oral contraceptives with different progestogen components. Lancet. 346:1995;1588-1593.
6. Hajjar K.A. Factor V Leiden - An unselfish gene? N Engl J Med. 331:1994;1585-1587.
7. Svensson P.I., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 330:1994;517-522.
8. Zoller B., Hillarp A., Berntorp E., Dahlbäck B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med. 48:1997;45-58.
9. Heijboer H., Brandjes D., Buller H.R., Sturk A., ten Cate J.W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein-thrombosis. N Engl J Med. 323:1991;1512-1516.
10. Ben-Tal O., Zivelin A., Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost. 61:1989;50-54.
11. Malm J., Laurell M., Nilsson I.M., Dahlback B. Thromboembolic disease - Critical evaluation of laboratory investigation. Thromb Haemost. 68:1992;7-13.
12. Ridker P.M., Miletich J.P., Hennekens C.H., Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women implications for venous thromboembolism screening. J Am Med Assoc. 277:1997;1305-1307.
13. Anderson F.A., Wheeler B., Goldberg R.J., Hosmer D.W., Patwardhan W.A., Jovanovic B., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism the Worcester DVT study. Arch Intern Med. 151:1991;933-938.
14. Hellgren M., Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 173:1995;210-213.
15. Schambeck C.M., Schwender S., Haubitz I., Geisen U.E., Grossman R.E., Keller F. Selective screening for the factor V Leiden mutation is it advisable prior to the prescription of oral contraceptives? Thromb Haemost. 78:1997;1490-1493.
16. Altès A., Souto J.C., Mateo J., Borrell M., Fontcuberta J. Activated protein C resistance assay when applied in the general population. Am J Obstet Gynecol. 176:1997;358-359.
17. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J. 146:1992;473-481.
18. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 133:1991;32-37.
19. Vandenbroucke JP, Koster T. Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V leiden mutation. Lancet 1994;344:1453-7.
20. Aillaud M.F., Suucco E., Alessi M.C., Gandois J.M., Gallian P., Morange P., et al. Resistance to activated protein C - Diagnostic strategy in a laboratory of haemostasis [letter]. Thromb Haemost. 74:1995;1197-1207.
21. United States Population Estimates by Age, Sex, Race, and Hispanic Origin, 1990 to 1995. Washington, DC: US Bureau of the Census, Population Division. Available at http://www.census.gov. Accessed July 16, 1998.
22. Wright R.O. Life and death in the United States statistics on life expectancies, diseases and death rates for the twentieth century. 1997;12-26 McFarland & Co, Jefferson (NC).
23. Guide to clinical preventative services. 2nd ed. 1996;39-92 Williams & Wilkins, Baltimore.
24. Kapiotis S., Quehenberger P., Jilma B., Handler S., Pabinger-Fasching I., Mannhalter C., et al. Improved characteristics of APC-resistance assay. Coatest aPC resistance by predilution of samples with factor V deficient plasma. Am J Clin Pathol. 106:1996;588-593.
25. Price D.T., Ridker P.M. Factor V Leiden mutation and the risks for thromboembolic disease a clinical perspective. Ann Intern Med. 127:1997;895-903.
26. Srtrobl F.J., Hoffman S., Huber S., Williams E.C., Voelkerding K.V. Activated protein C resistance assay performance. Improvement by sample dilution with factor V-deficient plasma. Arch Pathol Lab Med. 122:1998;430-433.
27. Beyth R.J., Cohen A.M., Landefeld S. Long-term outcomes of deep-vein thrombosis. Arch Intern Med. 155:1995;1031-1037.
28. Dahlback B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 90:1993;1004-1008.
29. Ries L.A.G., Kosary C.L., Hankey B.F., Miller B.A., Edwards B.K. SEER cancer statistics review, 1973-1995. 1998;National Cancer Institute, Bethesda (MD).
30. Salzmann P., Kerlikowske K., Phillips K. Cost-effectiveness of extending screening mammography to include women 40 to 49 years of age. Ann Intern Med. 127:1997;955-965.